NCT07342478 2026-05-14ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLLNewave Pharmaceutical IncPhase 3 Recruiting306 enrolled